



coordinated care™

# Anticonvulsants - pregabalin (LYRICA®)

## WA.PHAR.56 Anticonvulsant-Pregabalin (LYRICA)

Effective July 1, 2018

### Medical necessity

Drug	Medical Necessity
pregabalin (LYRICA®)	<p>LYRICA® may be considered medically necessary for any of the following diagnosis:</p> <ol style="list-style-type: none"> <li>1. Epilepsy/convulsions</li> <li>2. Diabetic peripheral neuropathy</li> <li>3. Fibromyalgia</li> <li>4. Neuropathic pain due to spinal cord injury</li> <li>5. Postherpetic neuralgia</li> </ol>

### Clinical policy:

Clinical Criteria	
Initial authorization criteria	<p><b>ONE</b> of the following:</p> <ol style="list-style-type: none"> <li>1. Diagnosis of Epilepsy/convulsions</li> <li>2. <b>ALL</b> of the following:               <ol style="list-style-type: none"> <li>a. Diagnosis of <b>ONE</b> of the following:                   <ol style="list-style-type: none"> <li>i. Diabetic peripheral neuropathy                       <ol style="list-style-type: none"> <li>1) Dose ≤ 300mg per day</li> </ol> </li> <li>ii. Fibromyalgia                       <ol style="list-style-type: none"> <li>1) Dose ≤ 450mg per day</li> </ol> </li> <li>iii. Neuropathic pain due to spinal cord injury                       <ol style="list-style-type: none"> <li>1) Dose ≤ 600mg per day</li> </ol> </li> <li>iv. Postherpetic neuralgia                       <ol style="list-style-type: none"> <li>1) Dose ≤ 600mg per day</li> </ol> </li> </ol> </li> <li>b. <b>ONE</b> of the following:                   <ol style="list-style-type: none"> <li>i. Client has been stable on Lyrica (pregabalin)</li> <li>ii. History of failure, contraindication, or intolerance to gabapentin 1800mg per day for 4 weeks</li> </ol> </li> <li>c. Client is greater than or equal to (≥) 12 years of age</li> </ol> </li> </ol> <p><b>Approval for 12 months</b></p>
Reauthorization criteria	<p><b>ONE</b> of the following:</p> <ol style="list-style-type: none"> <li>1. Diagnosis of Epilepsy/convulsions</li> <li>2. <b>BOTH</b> of the following:</li> </ol>

	<p>a. Dosage has not exceeded the above maximum limit for diagnosis</p> <p>b. Documentation of positive clinical benefit</p> <p><b>Approval for 12 months</b></p>
--	---

### Dosage and quantity limits

Diagnosis	Dose and Quantity Limits
<b>Diabetic peripheral neuropathy</b>	<ul style="list-style-type: none"> <li>• Maximum dose 300mg per day</li> <li>• Quantity limit 3 capsules per day</li> </ul>
<b>Fibromyalgia</b>	<ul style="list-style-type: none"> <li>• Maximum dose 450mg per day</li> <li>• Quantity limit 3 capsules per day</li> </ul>
<b>Neuropathic pain due to spinal cord injury</b>	<ul style="list-style-type: none"> <li>• Maximum dose 600mg per day</li> <li>• Quantity limit 3 capsules per day</li> </ul>
<b>Postherpetic neuralgia</b>	<ul style="list-style-type: none"> <li>• Maximum dose 600mg per day</li> <li>• Quantity limit 3 capsules per day</li> </ul>

### References

1. Product Information: LYRICA oral capsules, oral solution, pregabalin oral capsules, oral solution. Parke-Davis (per FDA), New York, NY, 2018.